Loading...
Pairing JAK with MEK for improved therapeutic efficiency in myeloproliferative disorders
The identification of JAK2 mutations as disease-initiating in myeloproliferative neoplasms (MPNs) has led to new and effective therapies for these diseases. In a study published in this issue of the JCI, Stivala et al. explored the key observation that JAK inhibition successfully suppresses MAPK act...
Na minha lista:
| Udgivet i: | J Clin Invest |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Clinical Investigation
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6436870/ https://ncbi.nlm.nih.gov/pubmed/30829649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI127582 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|